Epitope Dampening Monotypic Measles Virus Hemagglutinin Glycoprotein Results in Resistance to Cocktail of Monoclonal Antibodies

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Lech, Patrycja J ^a   Tobin, Gregory J ^b   Bushnell, Ruth ^b   Gutschenritter, Emily ^a   Pham, Linh D ^a   Nace, Rebecca ^a   Verhoeyen, Els ^c,d,e   Cosset, François Loïc ^c,d,e   Muller, Claude P ^f   Russell, Stephen J ^a   Nara, Peter L ^b,g  

^a MAYO CLINIC   (United States)

^b Biological Mimetics Inc   (United States)

^c CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITÉ LYON 1   (France)

^f LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^g IOWA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD150 ANTIGEN; EPITOPE; GLYCOPROTEIN; MEMBRANE COFACTOR PROTEIN; MONOCLONAL ANTIBODY; NECTIN 4; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; CELL FUSION; CONTROLLED STUDY; FEMALE; GLYCATION; MEASLES VIRUS; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; VIRUS ENTRY; VIRUS RESISTANCE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETINAE; EPITOPES; GLYCOSYLATION; HEMAGGLUTININS, VIRAL; HUMANS; MEASLES VACCINE; MEASLES VIRUS; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; MUTATION; NEUTRALIZATION TESTS; PLASMIDS; PROTEIN STRUCTURE, TERTIARY; RABBITS; RECOMBINANT PROTEINS; VERO CELLS;

MEASLES VIRUS;

EID: 84871914337     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052306     Document Type: Article

References (80)

1. Rota PA, Featherstone DA, Bellini WJ, (2009) Molecular epidemiology of measles virus. Curr Top Microbiol Immunol 330: 129-150.
2. Mathias RG, Meekison WG, Arcand TA, Schechter MT, (1989) The role of secondary vaccine failures in measles outbreaks. Am J Public Health 79: 475-478.
3. Edmonson MB, Addiss DG, McPherson JT, Berg JL, Circo SR, et al. (1990) Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. JAMA 263: 2467-2471.
4. Rota JS, Hummel KB, Rota PA, Bellini WJ, (1992) Genetic variability of the glycoprotein genes of current wild-type measles isolates. Virology 188: 135-142.
5. Tamin A, Rota PA, Wang ZD, Heath JL, Anderson LJ, et al. (1994) Antigenic analysis of current wild type and vaccine strains of measles virus. J Infect Dis 170: 795-801.
6. Klingele M, Hartter HK, Adu F, Ammerlaan W, Ikusika W, et al. (2000) Resistance of recent measles virus wild-type isolates to antibody-mediated neutralization by vaccinees with antibody. J Med Virol 62: 91-98.
7. Griffin D (2007) Measles Virus. In: Knipe D, editor. Fields Virology. Philadelphia: Lippincott Williams & Wilkins.
8. Bouche FB, Ertl OT, Muller CP, (2002) Neutralizing B cell response in measles. Viral Immunol 15: 451-471.
9. Brindley MA, Plemper RK, (2010) Blue native PAGE and biomolecular complementation reveal a tetrameric or higher-order oligomer organization of the physiological measles virus attachment protein H. J Virol 84: 12174-12184.
10. Navaratnarajah CK, Leonard VH, Cattaneo R, (2009) Measles virus glycoprotein complex assembly, receptor attachment, and cell entry. Curr Top Microbiol Immunol 329: 59-76.
11. Plemper RK, Brindley MA, Iorio RM, (2011) Structural and mechanistic studies of measles virus illuminate paramyxovirus entry. PLoS Pathog 7: e1002058.
12. Santiago C, Celma ML, Stehle T, Casasnovas JM, (2010) Structure of the measles virus hemagglutinin bound to the CD46 receptor. Nat Struct Mol Biol 17: 124-129.
13. Hashiguchi T, Ose T, Kubota M, Maita N, Kamishikiryo J, et al. (2011) Structure of the measles virus hemagglutinin bound to its cellular receptor SLAM. Nat Struct Mol Biol 18: 135-141.
14. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, et al. (1993) Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 67: 6025-6032.
15. Manchester M, Naniche D, Stehle T, (2000) CD46 as a measles receptor: form follows function. Virology 274: 5-10.
16. Manchester M, Eto DS, Valsamakis A, Liton PB, Fernandez-Munoz R, et al. (2000) Clinical isolates of measles virus use CD46 as a cellular receptor. J Virol 74: 3967-3974.
17. Erlenhofer C, Duprex WP, Rima BK, ter Meulen V, Schneider-Schaulies J, (2002) Analysis of receptor (CD46, CD150) usage by measles virus. J Gen Virol 83: 1431-1436.
18. Hsu EC, Iorio C, Sarangi F, Khine AA, Richardson CD, (2001) CDw150(SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus. Virology 279: 9-21.
19. Ferreira CS, Frenzke M, Leonard VH, Welstead GG, Richardson CD, et al. (2010) Measles virus infection of alveolar macrophages and dendritic cells precedes spread to lymphatic organs in transgenic mice expressing human signaling lymphocytic activation molecule (SLAM, CD150). J Virol 84: 3033-3042.
20. Noyce RS, Bondre DG, Ha MN, Lin LT, Sisson G, et al. (2011) Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog 7: e1002240.
21. Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, et al. (2011) Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 480: 530-533.
22. Schrag SJ, Rota PA, Bellini WJ, (1999) Spontaneous mutation rate of measles virus: direct estimation based on mutations conferring monoclonal antibody resistance. J Virol 73: 51-54.
23. Lauring AS, Andino R, (2010) Quasispecies theory and the behavior of RNA viruses. PLoS Pathog 6: e1001005.
24. Olofsson S, Hansen JE, (1998) Host cell glycosylation of viral glycoproteins-a battlefield for host defence and viral resistance. Scand J Infect Dis 30: 435-440.
25. Reitter JN, Desrosiers RC, (1998) Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein. J Virol 72: 5399-5407.
26. Mizuochi T, Matthews TJ, Kato M, Hamako J, Titani K, et al. (1990) Diversity of oligosaccharide structures on the envelope glycoprotein gp 120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. J Biol Chem 265: 8519-8524.
27. Mizuochi T, Spellman MW, Larkin M, Solomon J, Basa LJ, et al. (1988) Structural characterization by chromatographic profiling of the oligosaccharides of human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells. Biomed Chromatogr 2: 260-270.
28. Mizuochi T, Spellman MW, Larkin M, Solomon J, Basa LJ, et al. (1988) Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. Biochem J 254: 599-603.
29. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, et al. (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265: 10373-10382.
30. Hu A, Cattaneo R, Schwartz S, Norrby E, (1994) Role of N-linked oligosaccharide chains in the processing and antigenicity of measles virus haemagglutinin protein. J Gen Virol 75 (Pt 5) (): 1043-1052.
31. Santibanez S, Niewiesk S, Heider A, Schneider-Schaulies J, Berbers GA, et al. (2005) Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? J Gen Virol 86: 365-374.
32. Hashiguchi T, Maenaka K, Yanagi Y, (2011) Measles virus hemagglutinin: structural insights into cell entry and measles vaccine. Front Microbiol 2: 247.
33. Hashiguchi T, Maenaka K, Yanagi Y, (2008) X-ray crystallographic analysis of measles virus hemagglutinin. Uirusu 58: 1-10.
34. Duprex WP, McQuaid S, Hangartner L, Billeter MA, Rima BK, (1999) Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 73: 9568-9575.
35. Nara PL, Tobin GJ, Chaudhuri AR, Trujillo JD, Lin G, et al. (2010) How can vaccines against influenza and other viral diseases be made more effective? PLoS Biol 8: e1000571.
36. Tobin GJ, Trujillo JD, Bushnell RV, Lin G, Chaudhuri AR, et al. (2008) Deceptive imprinting and immune refocusing in vaccine design. Vaccine 26: 6189-6199.
37. Hashiguchi T, Kajikawa M, Maita N, Takeda M, Kuroki K, et al. (2007) Crystal structure of measles virus hemagglutinin provides insight into effective vaccines. Proc Natl Acad Sci U S A 104: 19535-19540.
38. Hu A, Sheshberadaran H, Norrby E, Kovamees J, (1993) Molecular characterization of epitopes on the measles virus hemagglutinin protein. Virology 192: 351-354.
39. Giraudon P, Wild TF, (1985) Correlation between epitopes on hemagglutinin of measles virus and biological activities: passive protection by monoclonal antibodies is related to their hemagglutination inhibiting activity. Virology 144: 46-58.
40. Ertl OT, Wenz DC, Bouche FB, Berbers GA, Muller CP, (2003) Immunodominant domains of the Measles virus hemagglutinin protein eliciting a neutralizing human B cell response. Arch Virol 148: 2195-2206.
41. de Carvalho Nicacio C, Williamson RA, Parren PW, Lundkvist A, Burton DR, et al. (2002) Neutralizing human Fab fragments against measles virus recovered by phage display. J Virol 76: 251-258.
42. Ziegler D, Fournier P, Berbers GA, Steuer H, Wiesmuller KH, et al. (1996) Protection against measles virus encephalitis by monoclonal antibodies binding to a cystine loop domain of the H protein mimicked by peptides which are not recognized by maternal antibodies. J Gen Virol 77 (Pt 10) (): 2479-2489.
43. Sheshberadaran H, Norrby E, (1986) Characterization of epitopes on the measles virus hemagglutinin. Virology 152: 58-65.
44. Giraudon P, Wild TF, (1981) Monoclonal antibodies against measles virus. J Gen Virol 54: 325-332.
45. Santiago C, Bjorling E, Stehle T, Casasnovas JM, (2002) Distinct kinetics for binding of the CD46 and SLAM receptors to overlapping sites in the measles virus hemagglutinin protein. J Biol Chem 277: 32294-32301.
46. Richardson CD, Choppin PW, (1983) Oligopeptides that specifically inhibit membrane fusion by paramyxoviruses: studies on the site of action. Virology 131: 518-532.
47. de Swart RL, Yuksel S, Langerijs CN, Muller CP, Osterhaus AD, (2009) Depletion of measles virus glycoprotein-specific antibodies from human sera reveals genotype-specific neutralizing antibodies. J Gen Virol 90: 2982-2989.
48. de Swart RL, Yuksel S, Osterhaus AD, (2005) Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J Virol 79: 11547-11551.
49. Woelk CH, Jin L, Holmes EC, Brown DW, (2001) Immune and artificial selection in the haemagglutinin (H) glycoprotein of measles virus. J Gen Virol 82: 2463-2474.
50. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, et al. (2005) Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23: 209-214.
51. Mudd PA, Ericsen AJ, Walsh AD, Leon EJ, Wilson NA, et al. (2011) CD8+ T cell escape mutations in simian immunodeficiency virus SIVmac239 cause fitness defects in vivo, and many revert after transmission. J Virol 85: 12804-12810.
52. Handel A, Regoes RR, Antia R, (2006) The role of compensatory mutations in the emergence of drug resistance. PLoS Comput Biol 2: e137.
53. Schierup MH, Mordhorst CH, Muller CP, Christensen LS, (2005) Evidence of recombination among early-vaccination era measles virus strains. BMC Evol Biol 5: 52.
54. Bankamp B, Takeda M, Zhang Y, Xu W, Rota PA, (2011) Genetic characterization of measles vaccine strains. J Infect Dis 204Suppl 1: S533-548.
55. Kolakofsky D, Roux L, Garcin D, Ruigrok RW, (2005) Paramyxovirus mRNA editing, the "rule of six" and error catastrophe: a hypothesis. J Gen Virol 86: 1869-1877.
56. Sidhu MS, Chan J, Kaelin K, Spielhofer P, Radecke F, et al. (1995) Rescue of synthetic measles virus minireplicons: measles genomic termini direct efficient expression and propagation of a reporter gene. Virology 208: 800-807.
57. Calain P, Roux L, (1993) The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 67: 4822-4830.
58. Finsterbusch T, Wolbert A, Deitemeier I, Meyer K, Mosquera MM, et al. (2009) Measles viruses of genotype H1 evade recognition by vaccine-induced neutralizing antibodies targeting the linear haemagglutinin noose epitope. J Gen Virol 90: 2739-2745.
59. Whittle H, Aaby P, Samb B, Cisse B, Kanteh F, et al. (1999) Poor serologic responses five to seven years after immunization with high and standard titer measles vaccines. Pediatr Infect Dis J 18: 53-57.
60. Mossong J, Nokes DJ, Edmunds WJ, Cox MJ, Ratnam S, et al. (1999) Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. Am J Epidemiol 150: 1238-1249.
61. Xiang JZ, Chen ZH, (1983) Measles vaccine in the People's Republic of China. Rev Infect Dis 5: 506-510.
62. Christenson B, Bottiger M, (1994) Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 12: 129-133.
63. Rota JS, Wang ZD, Rota PA, Bellini WJ, (1994) Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Res 31: 317-330.
64. Markowitz LE, Orenstein WA, (1990) Measles vaccines. Pediatr Clin North Am 37: 603-625.
65. Griffin DE, (1995) Immune responses during measles virus infection. Curr Top Microbiol Immunol 191: 117-134.
66. Ward BJ, Boulianne N, Ratnam S, Guiot MC, Couillard M, et al. (1995) Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 172: 1591-1595.
67. Pabst HF, Spady DW, Carson MM, Krezolek MP, Barreto L, et al. (1999) Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. Vaccine 17: 1910-1918.
68. Gans HA, Yasukawa LL, Alderson A, Rinki M, Dehovitz R, et al. (2004) T cell immunity to measles viral proteins in infants and adults after measles immunization. Viral Immunol 17: 298-307.
69. Gans HA, Yasukawa LL, Alderson A, Rinki M, DeHovitz R, et al. (2004) Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 190: 83-90.
70. Nakamura T, Peng KW, Vongpunsawad S, Harvey M, Mizuguchi H, et al. (2004) Antibody-targeted cell fusion. Nat Biotechnol 22: 331-336.
71. Tatsuo H, Ono N, Tanaka K, Yanagi Y, (2000) SLAM (CDw150) is a cellular receptor for measles virus. Nature 406: 893-897.
72. Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P, et al. (2005) Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem 280: 19543-19550.
73. Mellquist JL, Kasturi L, Spitalnik SL, Shakin-Eshleman SH, (1998) The amino acid following an asn-X-Ser/Thr sequon is an important determinant of N-linked core glycosylation efficiency. Biochemistry 37: 6833-6837.
74. Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G, et al. (1997) Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol 159: 279-289.
75. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, et al. (1995) Rescue of measles viruses from cloned DNA. EMBO J 14: 5773-5784.
76. Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, et al. (2009) Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 69: 82-91.
77. Hadac EM, Peng KW, Nakamura T, Russell SJ, (2004) Reengineering paramyxovirus tropism. Virology 329: 217-225.
78. Pham L, Nakamura T, Gabriela Rosales A, Carlson SK, Bailey KR, et al. (2009) Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome. J Gene Med 11: 197-206.
79. Ballew HC (1992) Neutralization; G.Lancz SSa, editor. New York: Elsevier.
80. World Health Organization Website. Media Center. Measles Fact sheet N°286 April 2012. http://www.who.int/mediacentre/factsheets/fs286/en/index.html Accessed 2012 December 5th.